Phantom Neuro, an Austin, TX-based neurotech company advancing human-machine interfaces, raised $19M Series A funding.
The round was led by Ottobock, with participation from Breakout Ventures, Draper Associates, LionBird Ventures, Time BioVentures, and Risk and Return, as well as new investors Actual VC, METIS Innovative, e1 Ventures, Jumpspace, MainSheet Ventures, and Brown Advisory.
The company intends to use the funds for preclinical testing, completion of first-in-human trials, regulatory submissions, and expanded research and development for broader control applications beyond prosthetic limbs.
Led by CEO and Founder Dr. Connor Glass, Phantom Neuro is a neurotechnology company developing a minimally invasive interface that enables intuitive control of prosthetic limbs and robotic exoskeletons. Its core platform, Phantom X, is designed to restore natural movement and functionality for amputees and individuals with mobility impairments, allowing robotic devices to function as seamless extensions of the human body.
This investment brought its total funding to $28M.
FinSMEs
15/04/2025